Northwestern University Feinberg School of Medicine

Parkinson's Disease and Movement Disorders Center

INTREPID STUDY: Implantable Neurostimulator for the Treatment of Parkinson’s Disease

Clinical Trial Investigator: Cindy Zadikoff, MD, Co-PI

This is a multi-center, prospective, double-blind, randomized (3:1), controlled, adaptive design study using the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system as a therapy for improving functional status in patients with advanced, levodopa-responsive Parkinson’s disease (PD), which is not adequately controlled with medication.

The primary objective of the study is to evaluate the safety and effectiveness of the system for bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy for improving the number of waking hours per day with good symptom control and no troublesome dyskinesia (ON time) in adults with advanced, levodopa-responsive bilateral Parkinson’s disease which is not adequately controlled with medication.

Clinical Trial Eligibility Criteria:

Research Study Visits: 14 Clinic Visits and 1 phone call over 5.5 years

Study Procedures:

Treatment: Medium-continuous stimulation or low-intermittent stimulation by the Boston Scientific DBS Vercise system (3:1 chance)

Compensation: $50-125 per study visit.

For More Information: Call us at 312-503-0755, or email

Funded by: Boston Scientific Corporation